Payment overview · 2025
General Payments
$107.44
5 reported records · 5 companies
Healthcare provider profile · identity verified
Jean B Stretton, MD
Allopathic & Osteopathic Physicians|Internal Medicine · WEST CHESTER, PA · NPI 1679532618
Verified facts
What the public records show
CMS Open Payments records show Jean B Stretton, MD received $107.44 in general payments during 2025 across 5 reported records.
SANOFI-AVENTIS U.S. LLC accounted for 30.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Synthroid by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $32.52 | 30.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $22.22 | 20.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.88 | 20.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.09 | 15.0% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $14.73 | 13.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $107.44 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $32.52 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $22.22 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.88 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $16.09 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.09 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $14.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 80 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 44 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
44 | 12 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
80 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 380 | 106 |
| Levothyroxine Sodium | Levothyroxine Sodium | 372 | 89 |
| Amlodipine Besylate | Amlodipine Besylate | 310 | 82 |
| Metoprolol Succinate | Metoprolol Succinate | 242 | 68 |
| Omeprazole | Omeprazole | 191 | 59 |
| Lorazepam | Lorazepam | 184 | 61 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 181 | 52 |
| Losartan Potassium | Losartan Potassium | 170 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 167 | 49 |
| Lisinopril | Lisinopril | 157 | 45 |
| Gabapentin | Gabapentin | 142 | 42 |
| Furosemide | Furosemide | 130 | 37 |
| Simvastatin | Simvastatin | 104 | 29 |
| Famotidine | Famotidine | 100 | 32 |
| Tramadol Hcl | Tramadol Hcl | 100 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 94 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 89 | 23 |
| Metformin Hcl | Metformin Hcl | 89 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 82 | 23 |
| Eliquis | Apixaban | 80 | 17 |
| Montelukast Sodium | Montelukast Sodium | 80 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 73 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 72 | 18 |
| Valsartan | Valsartan | 69 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 66 | 20 |
| Metformin Hcl Er | Metformin Hcl | 65 | 23 |
| Sertraline Hcl | Sertraline Hcl | 65 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 65 | 17 |
| Potassium Chloride | Potassium Chloride | 63 | 17 |
| Alprazolam | Alprazolam | 61 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 56 | 16 |
| Irbesartan | Irbesartan | 54 | 13 |
| Trazodone Hcl | Trazodone Hcl | 54 | 19 |
| Allopurinol | Allopurinol | 50 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 48 | 13 |
| Ezetimibe | Ezetimibe | 46 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 45 | suppressed |
| Azithromycin | Azithromycin | 44 | 41 |
| Synthroid | Levothyroxine Sodium | 44 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | suppressed |
| Clonazepam | Clonazepam | 39 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 38 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 38 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 37 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 37 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 34 | 11 |
| Finasteride | Finasteride | 34 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 33 | 16 |
| Mirtazapine | Mirtazapine | 32 | suppressed |
| Prednisone | Prednisone | 32 | 24 |
| Ipratropium Bromide | Ipratropium Bromide | 30 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 26 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Meloxicam | Meloxicam | 25 | 11 |
| Morphine Sulfate Er | Morphine Sulfate | 25 | suppressed |
| Ramipril | Ramipril | 25 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Jardiance | Empagliflozin | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Ozempic | Semaglutide | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Carvedilol | Carvedilol | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | 13 |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 15 |
| Celecoxib | Celecoxib | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Eszopiclone | Eszopiclone | 19 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 19 | 11 |
| Nitroglycerin | Nitroglycerin | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 13 |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Armour Thyroid | Thyroid,pork | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Repaglinide | Repaglinide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $107.44 · 5 records | SANOFI-AVENTIS U.S. LLC | Cologuard Collection Kit, ELIQUIS, SYNTHROID, TZIELD, UBRELVY, XIFAXAN | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error